MedPath

Role of Paclitaxel in Stricture Urethra

Not Applicable
Recruiting
Conditions
Stricture Urethra
Interventions
Procedure: DVIU
Procedure: DVIU with paclitaxel injection
Registration Number
NCT05678413
Lead Sponsor
Al-Azhar University
Brief Summary

Stricture urethra is a common disease and has various causing factors. The most common performed procedure is direct visual internal urethrotomy (DVIU), but unfortunately has a high recurrence rates. Multiple trial were performed to improve the outcomes of DVIU. Various intralesional injections were used. in this trial we will evaluate intralesional paclitaxel injection following DVIU.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
200
Inclusion Criteria
  • Anterior urethral stricture
  • Short strictures (less than 2 cm)
  • International Prostate Symptom Score less than 11 and maximum flow rate < 15 ml per second.
  • No previous treatment for stricture disease
Exclusion Criteria
  • Recurrent cases
  • Prior pelvic radiation
  • Associated other pathology or unresolved confounding etiologies (e.g. bladder neck contracture, neurogenic bladder, benign prostatic hyperplasia) were excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DVIUDVIUCystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue.
DVIU with paclitaxelDVIU with paclitaxel injectionCystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
Primary Outcome Measures
NameTimeMethod
Success of treatment1 year

Treatment free rates (Freedom from repeat intervention e.g., repeat dilation, DVIU or urethroplasty).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mohamed Fawzy Salman

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath